HRP20211252T1 - Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija - Google Patents
Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija Download PDFInfo
- Publication number
- HRP20211252T1 HRP20211252T1 HRP20211252TT HRP20211252T HRP20211252T1 HR P20211252 T1 HRP20211252 T1 HR P20211252T1 HR P20211252T T HRP20211252T T HR P20211252TT HR P20211252 T HRP20211252 T HR P20211252T HR P20211252 T1 HRP20211252 T1 HR P20211252T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- treatment
- use according
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100487 | 2017-10-17 | ||
| PCT/EP2018/078335 WO2019076947A1 (en) | 2017-10-17 | 2018-10-17 | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS |
| EP18800045.9A EP3697405B1 (en) | 2017-10-17 | 2018-10-17 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211252T1 true HRP20211252T1 (hr) | 2021-11-12 |
Family
ID=60484427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211252TT HRP20211252T1 (hr) | 2017-10-17 | 2018-10-17 | Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11903917B2 (https=) |
| EP (2) | EP3973960B1 (https=) |
| JP (3) | JP7227967B2 (https=) |
| KR (1) | KR102848960B1 (https=) |
| CN (2) | CN111479566B (https=) |
| AU (2) | AU2018351475A1 (https=) |
| CA (1) | CA3078424A1 (https=) |
| CY (1) | CY1124507T1 (https=) |
| DK (1) | DK3697405T3 (https=) |
| EA (1) | EA202090693A1 (https=) |
| ES (2) | ES3041322T3 (https=) |
| HR (1) | HRP20211252T1 (https=) |
| HU (1) | HUE055738T2 (https=) |
| LT (1) | LT3697405T (https=) |
| MX (2) | MX2020003473A (https=) |
| PL (1) | PL3697405T3 (https=) |
| PT (1) | PT3697405T (https=) |
| SI (1) | SI3697405T1 (https=) |
| WO (1) | WO2019076947A1 (https=) |
| ZA (1) | ZA202002069B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| WO2021037956A1 (en) | 2019-08-27 | 2021-03-04 | Atriva Therapeutics Gmbh | Combinations of mek inhibitors with cap-dependent endonuclease inhibitors |
| EP4041212B1 (en) * | 2019-10-08 | 2025-07-23 | Atriva Therapeutics GmbH | Mek inhibitors for the treatment of hantavirus infections |
| ES2995196T3 (en) * | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| CN112957361B (zh) * | 2021-03-24 | 2022-07-29 | 中国科学院武汉病毒研究所 | 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| AU2203800A (en) * | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| JP2003504400A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いた慢性痛の治療方法 |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| EP1467968A1 (en) | 2002-01-23 | 2004-10-20 | Warner-Lambert Company LLC | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| JP2007055983A (ja) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| EP2600862B1 (en) * | 2010-08-05 | 2016-04-20 | Case Western Reserve University | Inhibitors of erk for developmental disorders of neuronal connectivity |
| BR112015007616B1 (pt) * | 2012-10-08 | 2022-08-09 | Atriva Therapeutics Gmbh | Uso de inibidores de mek em combinação com oseltamivir, e composição farmacêutica e seu uso |
| EA039897B1 (ru) * | 2014-05-16 | 2022-03-24 | Атрива Терепьютикс Гмбх | Применение ингибитора мек для лечения коинфекции, включающей бактериальную инфекцию и инфекцию, вызванную вирусом гриппа |
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| EP4041212B1 (en) | 2019-10-08 | 2025-07-23 | Atriva Therapeutics GmbH | Mek inhibitors for the treatment of hantavirus infections |
| ES2995196T3 (en) | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2018
- 2018-10-17 US US16/756,720 patent/US11903917B2/en active Active
- 2018-10-17 ES ES21185183T patent/ES3041322T3/es active Active
- 2018-10-17 EA EA202090693A patent/EA202090693A1/ru unknown
- 2018-10-17 HU HUE18800045A patent/HUE055738T2/hu unknown
- 2018-10-17 WO PCT/EP2018/078335 patent/WO2019076947A1/en not_active Ceased
- 2018-10-17 LT LTEPPCT/EP2018/078335T patent/LT3697405T/lt unknown
- 2018-10-17 CN CN201880081184.5A patent/CN111479566B/zh active Active
- 2018-10-17 JP JP2020521541A patent/JP7227967B2/ja active Active
- 2018-10-17 CA CA3078424A patent/CA3078424A1/en active Pending
- 2018-10-17 DK DK18800045.9T patent/DK3697405T3/da active
- 2018-10-17 HR HRP20211252TT patent/HRP20211252T1/hr unknown
- 2018-10-17 MX MX2020003473A patent/MX2020003473A/es unknown
- 2018-10-17 AU AU2018351475A patent/AU2018351475A1/en not_active Abandoned
- 2018-10-17 ES ES18800045T patent/ES2883639T3/es active Active
- 2018-10-17 EP EP21185183.7A patent/EP3973960B1/en active Active
- 2018-10-17 CN CN202410133936.5A patent/CN118141795A/zh active Pending
- 2018-10-17 KR KR1020207013451A patent/KR102848960B1/ko active Active
- 2018-10-17 EP EP18800045.9A patent/EP3697405B1/en active Active
- 2018-10-17 SI SI201830351T patent/SI3697405T1/sl unknown
- 2018-10-17 PT PT188000459T patent/PT3697405T/pt unknown
- 2018-10-17 PL PL18800045T patent/PL3697405T3/pl unknown
-
2020
- 2020-05-04 ZA ZA2020/02069A patent/ZA202002069B/en unknown
- 2020-07-13 MX MX2022016066A patent/MX2022016066A/es unknown
-
2021
- 2021-08-24 CY CY20211100757T patent/CY1124507T1/el unknown
-
2023
- 2023-02-10 JP JP2023018912A patent/JP7618276B2/ja active Active
-
2024
- 2024-02-16 US US18/443,904 patent/US20240245637A1/en active Pending
- 2024-08-16 AU AU2024205853A patent/AU2024205853A1/en active Pending
- 2024-12-25 JP JP2024228526A patent/JP2025031917A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211252T1 (hr) | Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija | |
| JP2020537659A5 (https=) | ||
| JP2015534562A5 (https=) | ||
| HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| GB2503066A8 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| PH12020551264A1 (en) | Pyridone Derivative, Composition And Use As Antiviral Drug Thereof | |
| SA517382027B1 (ar) | أحماض 3-ألكيل-4-أميدو-ثنائية الحلقة [4، 5، 0] هيدروكساميك تعمل كمثبطات hdac | |
| MD20150092A2 (ro) | Derivate ale amidelor pentru tratamentul infecţiei cu HIV | |
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| MY159816A (en) | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them | |
| EA201792071A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| BR112017006920A8 (pt) | Inibidores de lisina gingipaína | |
| CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| BR112014029838A2 (pt) | formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida | |
| MX2019014201A (es) | Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas. | |
| ES2438690B1 (es) | Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis | |
| CO2019000513A2 (es) | Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un método de preparación de las mismas | |
| PL416447A1 (pl) | Inhibitory nukleazy (kompleksu polimerazy) wirusa grypy | |
| MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| UA112748C2 (uk) | Комбінована фармацевтична композиція та метод лікування та запобігання інфекційним хворобам |